Valink Therapeutics
Valink Therapeutics, formerly known as SpyCombinator, is a healthcare company based in London, UK, specializing in the development of next-generation antibody-based therapeutics for solid tumors.
Company Background
Valink Therapeutics, formerly known as SpyCombinator, is based in London, England, United Kingdom. Specializing in the healthcare industry with a focus on therapeutics, the company operates within the broader European region. Valink Therapeutics participated in the Y Combinator W21 batch.
Core Team Composition
Valink Therapeutics is comprised of a dedicated team of 10 members. The company’s small but proficient team is engaged in developing next-generation antibody-based therapeutics, particularly targeting solid tumors that current immunotherapies inadequately address.
Innovative Antibody-Based Therapeutics
Valink Therapeutics focuses on creating bispecific antibodies against cancer. The company utilizes a modular approach to rapidly generate and screen potential antibody-based drug candidates. Their technology aims to develop multifunctional antibody therapeutics to address unmet medical needs in the oncology sector.
Universal Assembly Platform™
Valink Therapeutics offers the Universal Assembly Platform™, a cutting-edge technology for constructing tailor-made drug candidates with specific geometries and target combinations. This platform was showcased at BioTrinity 2023, emphasizing its capacity for rapid generation and screening of antibody-based therapeutics through a five-dimensional design process.
Research and Development
The company's R&D efforts are centered on solid tumors and involve the iterative screening and design of drug candidates. By engaging in robust research methodologies, Valink Therapeutics aims to optimize and unlock new therapeutic possibilities using their innovative antibody technologies.
